Abstract
Cutaneous melanoma is the most deadly cutaneous neoplasm. In order to guide treatment decisions and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland were inaugurated in 2001 and revised in 2006 and 2016. Recent data on surgical and medical treatments from randomised trials necessitated modification of the treatment and follow-up recommendations.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Chemotherapy, Adjuvant
-
Dacarbazine / analogs & derivatives
-
Dacarbazine / therapeutic use
-
Dermatologic Surgical Procedures
-
Humans
-
Imidazoles / therapeutic use
-
Indoles / therapeutic use
-
Ipilimumab
-
Lymph Node Excision
-
Melanoma / pathology
-
Melanoma / therapy*
-
Neoplasm Staging
-
Nivolumab
-
Oximes / therapeutic use
-
Practice Guidelines as Topic
-
Radiotherapy, Adjuvant
-
Sentinel Lymph Node Biopsy
-
Skin Neoplasms / pathology
-
Skin Neoplasms / therapy*
-
Sulfonamides / therapeutic use
-
Switzerland
-
Temozolomide
-
Vemurafenib
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Imidazoles
-
Indoles
-
Ipilimumab
-
Oximes
-
Sulfonamides
-
Vemurafenib
-
Nivolumab
-
Dacarbazine
-
dabrafenib
-
Temozolomide